NexImmune, Inc.
NEXIDelisted Sep 6, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001538210
NexImmune, Inc. was delisted on Sep 6, 2024; its insiders filed their last Form 4 on Jun 13, 2024; 13 institutions reported holding it in 13F filings for Q2 2024, worth $408.6K in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by NexImmune, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for NexImmune, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Jones Kristi | President and CEO | 1 | Jun 13, 2024 | 0 |
| Roemer Alan S. | Director | 0 | Nov 22, 2023 | 0 |
| Barer Sol J | Director | 2,217,814 | Jul 7, 2023 | 0 |
| Yao Zhengbin | Director | – | Jul 7, 2023 | 0 |
| Bertram Timothy | Director | – | Jul 7, 2023 | 0 |
| D'Angio Paul | Director | – | Jul 7, 2023 | 0 |
| Verstandig Grant | Director | 1,053,619 | Jul 7, 2023 | 0 |
| Gandhi Leena | Director | – | Jul 7, 2023 | 0 |
| Trainer John | Chief Financial Officer | 186,969 | Apr 6, 2023 | 0 |
| Oelke Mathias | Chief Science Officer | 134,023 | Apr 6, 2023 | 0 |
| Zeldis Jerome B | Executive VP of Research & Dev | – | Apr 7, 2022 | 0 |
| Knight Robert Douglas | Chief Medical Officer | – | Apr 7, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 21, 2022 (view filing) | Mar 18 | 3 days | Barer Sol JDirector | PPurchase | +30.0K | $2.11 | +$63.3K | +2.1%1.45M after | |
| Mar 22, 2022 (view filing) | Mar 21 | 1 day | Barer Sol JDirector | PPurchase | +30.0K | $2.14 | +$64.2K | +2.1%1.48M after | |
| Mar 23, 2022 (view filing) | Mar 22 | 1 day | Barer Sol JDirector | PPurchase | +30.0K | $2.41 | +$72.3K | +2.0%1.51M after | |
| Mar 24, 2022 (view filing) | Mar 23 | 1 day | Barer Sol JDirector | PPurchase | +10.0K | $2.67 | +$26.7K | +0.7%1.52M after | |
| Mar 28, 2022 (view filing) | Mar 24-28 | 4 days | Verstandig GrantDirector | PPurchase | +190.6K | $3.94 | +$750.3K | +26.7%905.5K after | 3 lots |
| Mar 30, 2022 (view filing) | Mar 29 | 1 day | Jones KristiPresident and CEO | PPurchase | +10.0K | $3.74 | +$37.4K | +15.9%73.1K after | |
| Jun 2, 2022 (view filing) | May 31-Jun 2 | 2 days | Barer Sol JDirector | PPurchase | +100.0K | $2.26 | +$226.0K | +6.9%1.56M after | 3 lots |
| Jun 2, 2022 (view filing) | May 31-Jun 2 | 2 days | Verstandig GrantDirector | PPurchase | +133.1K | $2.23 | +$297.5K | +16.3%950.5K after | 3 lots |
| Jun 7, 2022 (view filing) | Jun 3-7 | 4 days | Verstandig GrantDirector | PPurchase | +66.9K | $2.21 | +$148.1K | +6.8%1.05M after | 3 lots |
| Nov 17, 2022 (view filing)8:40 PM ET | Nov 16-17 | 1 day | Barer Sol JDirector | PPurchase | +200.0K | $0.4811 | +$96.2K | +13.0%1.74M after | 2 lots |
| Mar 31, 2023 (view filing)4:56 PM ET | Mar 30 | 1 day | Barer Sol JDirector | PPurchase | +400.0K | $0.4103 | +$164.1K | +22.0%2.22M after | |
| Nov 22, 2023 (view filing) | Nov 21-22 | 1 day | Roemer Alan S.Director | SSale | −7.83K | $2.05 | −$16.0K | −100.0%0 after | 2 lots |
| Jun 13, 2024 (view filing)7:58 PM ET | Jun 11 | 2 days | Jones KristiPresident and CEO | PPurchaseSeries A Preferred Stock, par value $0.0001 per share | +1 | $0.01 | +$0.01 | New position1 after |